Management of thrombocytopenia with ENHERTU

Thrombocytopenia can occur in patients treated with ENHERTU.1

  • Of the 257 patients with unresectable or metastatic HER2+ breast cancer who received ENHERTU 5.4 mg/kg in DESTINY-Breast03, the incidence of platelet count decrease2
    • Grade 1 incidence 13.2%; Grade 2 incidence 5.1%; Grade 3 incidence 6.2%; Grade 4 incidence 1.2%
  • Based on the severity of thrombocytopenia, manage through treatment interruption or dose reduction.1 See below for dose modifications

Dose modifications for thrombocytopenia1

Severity Treatment modification
Grade 3
(platelets less than
50 to 25 x 109/L)
  • Interrupt ENHERTU until resolved to Grade 1 or less, then maintain dose
Grade 4
(platelets less than
25 x 109/L)

Toxicity grades are in accordance with NCI-CTCAE v.5.0.

Get ENHERTU Resources for You and Your Practice

Ready to learn more about ENHERTU?
HER2, human epidermal growth factor receptor 2; NCI-CTCAE, National Cancer Institute–Common Terminology Criteria for Adverse Events.